Industry Projects | Projects by Region | Projects by Category | Archived Projects | Project Gallery
 

Pirfenidone – Treatment for Idiopathic Pulmonary Fibrosis



IPF mainly involves cellular proliferation and enhanced biosynthesis which is caused by cytokine growth factors.


Back to Project Details



Related Projects

Fablyn (Lasofoxifene) - Investigational SERM
The product of a joint development programme between Pfizer and...

Exanta - Oral Direct Thrombin Inhibitor for the
Exanta (ximelagatran) is an oral Direct Thrombin Inhibitor (DTI)...

Lipitor / Torcetrapib - Combination Therapy
Under development by Pfizer, torcetrapib is a member of the cholesteryl...

Acomplia (Rimonabant) - Investigational Agent for
Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective...

Erbitux (Cetuximab)
Erbitux is a chimaeric monoclonal antibody (MAb) that is specific for...

See all projects


Contact us
Advertise with us
Terms and conditions
Privacy
Links
Newsletter sign up
Online magazine sign up

drugdevelopment-technology.com is a product of Net Resources International. Copyright 2011 Net Resources International, a trading division of SPG Media Limited.